Table 2.
Common core of transcripts significantly deregulated by bexarotene and gefitinib treatments in mammary epithelium from p53-null mice.
| Tag | Gene | Description | Fold change* | B | G | T |
|---|---|---|---|---|---|---|
| Transcriptional regulation /signal transduction | ||||||
| CATCTGTATT | Fosl2 | Fos-like antigen 2 | 6.0 | ↑ | ↑ | - |
| GGTTTTGTTT | Wsb1 | WD repeat and SOCS box-containing 1 | 6.2 | ↑ | ↑ | - |
| GGATATGTGG | Egr1 | Early growth response 1 | 2.1 | ↑ | ↑ | ↓ |
| GCGCCCTTCC | Ccl21b | Chemokine (C-C motif) ligand 21b | −2.8 | ↓ | ↓ | ↑ |
| GATTTCTGTC | Gng5 | Guanine nucleotide binding protein gamma 5 | −1.7 | ↓ | ↓ | ↑ |
| Cell cycle /proliferation | ||||||
| AAATCCTTTC | Ptn | Pleiotrophin | 2.6 | ↑ | ↑ | - |
| TATAGTATGT | Glul | Glutamate-ammonia ligase | 1.9 | ↑ | ↑ | ↓ |
| CAGCATAAAT | Dip3b | Dip3 beta | −7.2 | ↓ | ↓ | - |
| GCCAAACCAA | Clk1 | CDC-like kinase 1 | −1.9 | ↓ | ↓ | - |
| Cytoskeleton organization / extracellular matrix remodeling | ||||||
| CTCCTGGACA | Gsn | Gelsolin | 3.1 | ↑ | ↑ | - |
| TTAACTCTGA | Prelp | Proline arginine-rich end leucine-rich repeat | 2.8 | ↑ | ↑ | - |
| CCCTGAGTCC | Actb | Actin, beta, cytoplasmic | 2.5 | ↑ | ↑ | - |
| CTGAGGAAGT | Sparcl1 | SPARC-like 1 | 2.1 | ↑ | ↑ | - |
| ATAGCCCCAA | Ctss | Cathepsin S | −5.1 | ↓ | ↓ | ↑ |
| TTTTATTCTC | Capn12 | Calpain 12 | −6.0 | ↓ | ↓ | - |
| GGCTGTTGAA | Csrp1 | Cysteine and glycine-rich protein 1 | −1.6 | ↓ | ↓ | - |
| Protein metabolism | ||||||
| TTACCATTGC | Tiparp | TCDD-inducible poly(ADP-ribose) polymerase | 2.8 | ↑ | ↑ | ↓ |
| CCAGGTTATT | Nola3 | Nucleolar protein family A, member 3 | −6.5 | ↓ | ↓ | - |
| TGACCCCGGG | Uba52 | Ubiquitin A-52 residue ribosomal protein | −2.3 | ↓ | ↓ | - |
| TGGTGTAGGA | Hspa5 | Heat shock 70kD protein 5 | −1.5 | ↓ | ↓ | - |
| TGGGTTGTCT | Tpt1 | Tumor protein translationally-controlled 1 | −1.5 | ↓ | ↓ | - |
| GTGAAACTAA | Rps4x | Ribosomal protein S4, X-linked | −1.5 | ↓ | ↓ | - |
| CTAATAAAGC | Fau | Finkel-Biskis-Reilly murine sarcoma virus | −1.3 | ↓ | ↓ | - |
| Miscellaneous | ||||||
| TGGATCCTGA | Hbb-b1 | Hemoglobin, beta adult major chain | 15.5 | ↑ | ↑ | - |
| TAAATTAAGA | Hexb | Hexosaminidase B | 8.5 | ↑ | ↑ | - |
| GAGGACTGCC | Ly6e | Lymphocyte antigen 6 complex, locus E | 6.2 | ↑ | ↑ | - |
| CCCTTCTTCT | Hba-a1 | Hemoglobin alpha, adult chain 1 | 3.3 | ↑ | ↑ | - |
| CCAGGCCTTA | Crip1 | Cysteine-rich protein 1 | 2.2 | ↑ | ↑ | - |
| TGCACTATTG | 1500012F01 | RIKEN cDNA 1500012F01 gene | −4.4 | ↓ | ↓ | - |
| AACTAGAAAA | Ndufs2 | NADH dehydrogenase Fe-S protein 2 | −4.2 | ↓ | ↓ | ↑ |
| TAAGGGAAAT | Tpi1 | Triosephosphate isomerase 1 | −2.3 | ↓ | ↓ | ↑ |
| CCAAATAAAA | Ldha | Lactase dehydrogenase A | −2.2 | ↓ | ↓ | ↑ |
| CTAATAAAAG | Cox4i1 | Cytochrome c oxidase subunit IV isoform 1 | −2.1 | ↓ | ↓ | - |
| TAAAGCAAAA | Hist1h2bc | Histone 1, H2bc | −1.9 | ↓ | ↓ | - |
*
Up-regulated transcripts are represented by positive average fold changes and down-regulated transcripts are represented by negative average fold changes among bexarotene and gefitinib treatments. B: Bexarotene treatment, G: Gefitinib treatment, T: p53-null mammary tumors.